Author

M. M. H. Li

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:statistical model· 1

Frequent Co-Authors

S. Huang· 3 shared J. A. Wohlschlegel· 2 shared Y. Jami-Alahmadi· 2 shared A. J. O'Donoghue· 1 shared B. Jagodzinska· 1 shared C. Yeun· 1 shared D. Enard· 1 shared E. Yang· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

S. Huang

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Positive selection analyses identify a single WWE domain residue that shapes ZAP into a super restriction factor

S. Huang, J. Girdner, L. P. Nguyen, D. Enard, M. M. H. Li

This study identifies a single residue in ZAP's WWE domain that enhances its antiviral activity against alphaviruses by improving viral translation inhibition.

bioRxiv · Nov 20, 2023 · PreprintMicrobiology

Chikungunya virus glycoproteins transform macrophages into productive viral dissemination vessels.

M. M. H. Li, Z. Yao, S. Ramachandran, S. Huang, Y. Jami-Alahmadi, J. A. Wohlschlegel

This study identifies CHIKV glycoproteins E2 and E1 as key factors that enable macrophages to support viral replication and dissemination by counteracting host restriction factors.

bioRxiv · May 29, 2023 · PreprintMicrobiology

Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an Mpro Protease Inhibitor for Treatment of SARS-CoV-2

J. Campagna, B. Jagodzinska, P. Alvarez, C. Yeun, P. Spilman, K. M. Enquist, W. Cohn, P. Fajtov, A. J. O'Donoghue, V. Arumugaswami, M. M. H. Li, R. Damoiseaux, V. John

The paper identifies eltrombopag as a PLpro inhibitor that can be repurposed for SARS-CoV-2 treatment, effective in combination with Mpro inhibitors.

bioRxiv · Jul 18, 2022Microbiology

Substrate trapping approach identifies TRIM25 ubiquitination targets involved in diverse cellular and antiviral processes

E. Yang, S. Huang, Y. Jami-Alahmadi, G. McInerney, J. A. Wohlschlegel, M. M. H. Li

bioRxiv · Mar 17, 2022 · PreprintCell Biology